Disease or Syndrome: Allergic Fungal Rhinosinusitides

FDA approves Dupixent for allergic fungal rhinosinusitis

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a history of sino-nasal surgery.